Determination of rearrangements in ALK gene in selected russian population of patients with non-small cell lung cancer
https://doi.org/10.18027/2224-5057-2013-3-3-9
Abstract
Determination of rearrangements in ALK gene in patients with non-small cell lung cancer (NSCLC), proposed as a mandatory procedure in most current international guidelines for the diagnosis and treatment of cancer. The aim of the study was to conduct a test by fluorescent hybridization in situ (FISH) of translocations involving ALK gene in patients referred for testing for EGFR gene mutations in the framework of the Society of oncologists-chemotherapeutists "Improvement of molecular genetic diagnosis in order to improve the efficiency of anticancer treatment» www.cancergenome.ru. Successful tests conducted in 189 out of 200 patients with NSCLC without mutations EGFR. There 12 positive tests (6.3%). The dependence of the frequency of detection of gene rearrangements of the ALK histological forms of cancer, smoking status and age of the patient was shown. The efficiency of wide FISH testing for ALK gene rearrangements in patients with glandular histological types of NSCLC was confirmed.
About the Authors
I. A. Demidova
ГБУЗ МГОБ 62 ДЗМ, лаборатория молекулярной диагностики
Russian Federation
Russian Federation
E. O. Tsepenshchikova
ГБУЗ МГОБ 62 ДЗМ, лаборатория молекулярной диагностики
Russian Federation
Russian Federation
A. A. Barinov
ГБУЗ МГОБ 62 ДЗМ, лаборатория молекулярной диагностики
Russian Federation
Russian Federation
I. M. Gagarin
ГБУЗ МГОБ 62 ДЗМ, лаборатория молекулярной диагностики
Russian Federation
Russian Federation
N. A. Savelov
ГБУЗ МГОБ 62 ДЗМ, отделение патологической анатомии
Russian Federation
Russian Federation
V. N. Grinevich
ГБУЗ МГОБ 62 ДЗМ, отделение патологической анатомии
Russian Federation
Russian Federation
S. A. Tyulyandin
ГБУ РОНЦ им. Н. Н. Блохина РАМН, отделение клинической фармакологии и химиотерапии
Russian Federation
Russian Federation
References
1. American Cancer Society, Cancer Facts & Figures 2012, http://www.cancer.
2. org / Research / CancerFactsFigures / 2013
3. Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never smokers — A review. Eur. J. Cancer. 2012;48 (9):1299-1311.
4. Food and Drug Administration (2011) Summary review (application number: 202570Orig1s000). Food and Drug Administration, Silver Spring.
5. Lindeman LI, Gagle PT, Beasley MB et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013; 137 (6):828-60.
6. Thunnissen E, Bubbendorf L, Dietel M et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461 (3):245-57.
7. John A. Kiernan, Formaldehyde, formalin, paraformaldehyde and glutaraldehyde: What they are and what they do. Microscopy Today 2000; 00-1 pp. 8-12.
8. Yan F, Wu X, Crawford M et al. The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods. Methods. 2010; 52 (4):281-6.
9. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract 2501]. J. Clin Oncol. 2011; 29 (suppl): 165s.
10. Crino L, Kim D-W, Riely G, et al. Initial phase 2 results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 7514]. J Clin Oncol. 2011;29 (suppl): 479s.
11. An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS ONE 2012;7: e40109.
12. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46:1773-80.
13. Demidova I., Savelov N., Barinov A, et al. Immunohistochemistry, Fluorescence in Situ Hybridization and Reverse Transcription-Polymerase Chain Reaction for the Detection of Anaplastic Lymphoma Kinase Gene Rearrangements in Non-Small Cell Lung Cancer Patients: Potential Advantages and Methodological Pitfalls. Arch Pathol Lab Med 2013, in press.
14. Nishino M, Klepeis V, Yeap B, et al. Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol.2012; 25 (11):1462-72.
15. Horn L, Pao W. EML4-ALK: Honing In on a New Target in Non — Small-Cell Lung Cancer J Clin Oncol 2009, 27 (26):4232-4235.
16. Rodig S, Mino-Kenudson M, Dacic S, et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population. Clin Cancer Res 2009;15 (16): 5216-5223.
17. Atherly A, Camidge R. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British Journal of Cancer (2012) 106, 1100-1106.
18. Weickhardt AJ, Camidge DR. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin Invest 2011; 1 (8): 1119-1126.
19. Show AT, Yeap BY, Mino-Kenudson M et al. Clinical Features
20. and Outcome of Patients With Non — Small-Cell Lung Cancer Who Harbor EML4-ALK. J Clin Oncol 2009; 27 (26): 4248-4253.
21. Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22:508-515, 2009.
22. Wong DW, Leung EL, So KK, et al: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:1723-1733, 2009.
23. Paik HJ, Choi CM, Kim H et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer. A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012; 76:403-409.
24. Paik HJ, Choi CM, Kim H et al. Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer. J Thor Oncol 2011; 6 (3) 266-472.
25. Just P-A, Cazes A, Audebourg A, et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers. Lung Cancer 2011, 76 (3):309-315.
26. Garrido P, de Castro J, Coucha A, et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol 2012; 14:338-349.
Review
For citations:
Demidova I.A., Tsepenshchikova E.O., Barinov A.A., Gagarin I.M., Savelov N.A., Grinevich V.N., Tyulyandin S.A. Determination of rearrangements in ALK gene in selected russian population of patients with non-small cell lung cancer. Malignant tumours. 2013;(3):3-9. (In Russ.) https://doi.org/10.18027/2224-5057-2013-3-3-9
Views:
1046
Email this article 